Management Focused on Corporate Value and the Common Interests of Shareholders
First written in FY2016. 8 of 9 entries say "Restated". Latest entry: FY2020-Q3.
72 other companies' latest entry also says "Restated".
- FY2020-Q3RestatedAnnual report
「The Company will deeply recognise its social mission and responsibilities as a pharmaceutical company, thoroughly comply with laws and regulations under high ethical standards, and work to strengthen relationships of trust with shareholders and other stakeholders.」
The Company continues to pursue a management stance that prioritises its social mission, compliance with laws and regulations, relationships of trust with stakeholders and corporate value enhancement. - FY2019-Q3RestatedAnnual report
「The Company is pursuing management focused on enhancing corporate value by deeply recognising its social mission and responsibilities as a pharmaceutical company, thoroughly complying with laws and regulations under high ethical standards, and working to strengthen relationships of trust with shareholders and other stakeholders.」
The Company's management stance of prioritising its social mission, compliance with laws and regulations, relationships of trust with stakeholders and corporate value enhancement is restated. - FY2019-Q2RestatedAnnual report
「The Company is pursuing management focused on enhancing corporate value by deeply recognising its social mission and responsibilities as a pharmaceutical company, thoroughly complying with laws and regulations under high ethical standards, and working to strengthen relationships of trust with shareholders and other stakeholders.」
The Company's management stance of prioritising its social mission, compliance with laws and regulations, relationships of trust with stakeholders and corporate value enhancement is restated. - FY2018-Q3RestatedAnnual report
「The Company is pursuing management focused on enhancing corporate value by deeply recognising its social mission and responsibilities as a pharmaceutical company, thoroughly complying with laws and regulations under high ethical standards, and working to strengthen relationships of trust with shareholders and other stakeholders.」
The Company's management stance of prioritising its social mission, compliance with laws and regulations, relationships of trust with stakeholders and corporate value enhancement is restated. - FY2018-Q1RestatedAnnual report
「The Company is pursuing management focused on enhancing corporate value by deeply recognising its social mission and responsibilities as a pharmaceutical company, thoroughly complying with laws and regulations under high ethical standards, and working to strengthen relationships of trust with shareholders and other stakeholders.」
The Company's management stance of prioritising compliance with laws and regulations, relationships of trust with stakeholders and corporate value enhancement is restated. - FY2017RestatedAnnual report
「The Company plans to pursue management focused on enhancing corporate value by deeply recognising its social mission and responsibilities as a pharmaceutical company, thoroughly complying with laws and regulations under high ethical standards, and working to strengthen relationships of trust with shareholders and other stakeholders.」
The Company's management stance of prioritising its social mission, compliance with laws and regulations, relationships of trust with stakeholders and corporate value enhancement is reaffirmed. - FY2017-Q3RestatedAnnual report
「The Company is pursuing management focused on enhancing corporate value by deeply recognising its social mission and responsibilities as a pharmaceutical company, thoroughly complying with laws and regulations under high ethical standards, and working to strengthen relationships of trust with shareholders and other stakeholders.」
The Company's management stance of prioritising compliance with laws and regulations, relationships of trust with stakeholders and corporate value enhancement is restated. - FY2017-Q1RestatedAnnual report
「The Company is pursuing management focused on enhancing corporate value by deeply recognising its social mission and responsibilities as a pharmaceutical company, thoroughly complying with laws and regulations under high ethical standards, and working to strengthen relationships of trust with shareholders and other stakeholders.」
The Company's management stance of prioritising corporate value enhancement, relationships of trust with stakeholders and compliance with laws and regulations is restated. - FY2016First statedAnnual report
「The Company is pursuing management focused on enhancing corporate value by working to strengthen relationships of trust with shareholders and other stakeholders.」
Long-term research and development investment, governance, compliance and enhancing shareholder interests are presented as the framework for improving corporate value.